NCT01762839 - A Study to Assess the Cardiac Safety of Oritavancin in Healthy Participants | Biotech Hunter

Enrollment

150

Participants

Timeline

Start Date

December 27, 2012

Primary Completion Date

January 31, 2013

Study Completion Date

February 11, 2013

Conditions

Healthy

Interventions

DRUG

Single-Dose IV Oritavancin Diphosphate

Intravenous oritavancin was administered via 2 dedicated, peripheral venous lines, 1 in each arm. The infusion lasted approximately 3 hours.

DRUG

Placebo

Intravenous placebo was administered via 2 dedicated, peripheral venous lines, 1 in each arm. The infusion lasted approximately 3 hours.

DRUG

Moxifloxacin

Participants randomized to the open-label moxifloxacin treatment arm only received a 400-mg moxifloxacin tablet and did not receive a placebo infusion.

Trial Locations (1)

53095

Spaulding Clinical, West Bend